Swiss National Bank Acquires 18,600 Shares of Insmed Incorporated (NASDAQ:INSM)

Swiss National Bank grew its position in Insmed Incorporated (NASDAQ:INSM - Free Report) by 6.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 321,100 shares of the biopharmaceutical company's stock after purchasing an additional 18,600 shares during the quarter. Swiss National Bank owned approximately 0.18% of Insmed worth $22,169,000 as of its most recent filing with the SEC.

A number of other institutional investors have also bought and sold shares of INSM. Jennison Associates LLC lifted its stake in shares of Insmed by 0.6% in the 4th quarter. Jennison Associates LLC now owns 773,813 shares of the biopharmaceutical company's stock valued at $53,424,000 after purchasing an additional 4,560 shares during the period. Capital CS Group LLC acquired a new position in Insmed in the fourth quarter valued at approximately $586,000. Orion Portfolio Solutions LLC boosted its holdings in shares of Insmed by 48.5% during the 3rd quarter. Orion Portfolio Solutions LLC now owns 28,087 shares of the biopharmaceutical company's stock worth $2,050,000 after buying an additional 9,170 shares in the last quarter. Ally Bridge Group NY LLC boosted its holdings in shares of Insmed by 16.9% during the 3rd quarter. Ally Bridge Group NY LLC now owns 150,833 shares of the biopharmaceutical company's stock worth $11,011,000 after buying an additional 21,833 shares in the last quarter. Finally, Vestal Point Capital LP grew its position in shares of Insmed by 113.3% during the 3rd quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company's stock worth $116,800,000 after buying an additional 850,000 shares during the period.

Remove Ads

Insider Activity at Insmed

In other news, CEO William Lewis sold 18,750 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $77.03, for a total transaction of $1,444,312.50. Following the completion of the transaction, the chief executive officer now directly owns 334,186 shares of the company's stock, valued at $25,742,347.58. This represents a 5.31 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Sara Bonstein sold 3,470 shares of Insmed stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $65.70, for a total transaction of $227,979.00. Following the completion of the sale, the chief financial officer now directly owns 114,736 shares in the company, valued at $7,538,155.20. This trade represents a 2.94 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 550,957 shares of company stock worth $42,992,528. 4.60% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on INSM shares. UBS Group increased their target price on shares of Insmed from $105.00 to $110.00 and gave the stock a "buy" rating in a research note on Thursday, March 6th. Stifel Nicolaus reduced their target price on Insmed from $97.00 to $96.00 and set a "buy" rating for the company in a research note on Friday, February 21st. Morgan Stanley upped their price target on Insmed from $85.00 to $90.00 and gave the stock an "overweight" rating in a research note on Thursday, February 6th. Wells Fargo & Company raised their price objective on Insmed from $85.00 to $107.00 and gave the company an "overweight" rating in a research note on Wednesday, February 19th. Finally, Truist Financial boosted their price objective on Insmed from $105.00 to $108.00 and gave the company a "buy" rating in a report on Friday, February 21st. One investment analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $94.00.

Insmed Stock Performance

Shares of NASDAQ INSM traded up $1.15 during midday trading on Friday, reaching $79.92. The company's stock had a trading volume of 1,923,345 shares, compared to its average volume of 2,173,512. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The stock has a market capitalization of $14.47 billion, a P/E ratio of -14.30 and a beta of 1.28. The firm has a 50 day moving average price of $77.14 and a 200-day moving average price of $73.77. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $84.91.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.15). The business had revenue of $104.44 million during the quarter, compared to the consensus estimate of $102.31 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. As a group, equities analysts predict that Insmed Incorporated will post -4.56 earnings per share for the current year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.